Scynexis (SCYX) Misses Q1 EPS by 29c May 11, 2026 04:35PM
Scynexis (SCYX) files 87M share offering by selling stockholders May 1, 2026 04:05PM
SCYNEXIS (SCYX) PT Lowered to $3.42 at Brookline Capital Markets Mar 9, 2026 04:19PM
SCYNEXIS receives FDA designations for antifungal drug SCY-247 Jan 21, 2026 08:01AM
SCYNEXIS receives 180-day Nasdaq extension until June 15, 2026 Dec 22, 2025 08:02AM


Nov 17, 2025 10:16AM SCYNEXIS receives $7 million annual federal grant for antifungal research
Nov 5, 2025 05:00PM Scynexis (SCYX) Tops Q3 EPS by 3c
Oct 28, 2025 07:14AM SCYNEXIS (SCYX) PT Lowered to $3 at Guggenheim
Oct 23, 2025 04:02PM SCYNEXIS (SCYX) PT Lowered to $4 at Benchmark
Aug 13, 2025 06:11PM Scynexis (SCYX) Tops Q2 EPS by 6c
May 28, 2025 08:31AM Scynexis (SCYX) resumes dosing in Phase 3 study of ibrexafungerp
May 15, 2025 04:25PM Scynexis (SCYX) Tops Q1 EPS by 10c
Apr 8, 2025 08:05AM Scynexis (SCYX) to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases
Nov 6, 2024 05:04PM Scynexis (SCYX) Tops Q3 EPS by 8c
Aug 8, 2024 06:23PM Scynexis (SCYX) Misses Q2 EPS by 15c
Jul 23, 2024 07:02AM Scynexis (SCYX) to Receive $10M Milestone Payment from GSK